AUSTIN, Texas, December 12, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare ...
NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla., December 15, 2025--(BUSINESS WIRE)--NeoGenomics, Inc.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology ...
NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic ...
Canaccord raised the firm’s price target on Natera (NTRA) to $285 from $260 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes ...
Justin Flynn is an editor and writer from Ireland. He became a gamer at the age of eight when a mix-up at his local toy store landed him a copy of Kingdom Hearts. Since then, he has earned a Bachelor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback